Prostate Cancer Hormone Therapy: How Long Does It Last? (2026 Update)

There's no single standard duration for hormone therapy in prostate cancer — it varies depending on risk group and stage. In high-risk or locally advanced disease treated with radiation, several years of combined hormone therapy is part of the standard approach; in intermediate-risk disease, only a short course alongside radiation may be used; and in metastatic disease, hormone therapy becomes the long-term backbone of treatment.

Key Takeaways

• Hormone therapy duration is not uniform — it differs across low-risk, intermediate-risk, high-risk, and metastatic stages.
• If radiation therapy is chosen for intermediate-risk disease, a short course of hormone therapy may be added depending on specific conditions.
• For high-risk or locally advanced disease treated with radiation, combining hormone therapy over several years is part of the standard of care.
• In metastatic disease, hormone therapy becomes the central axis of treatment, and it is now standard to combine it from the start with stronger anti-androgen agents or chemotherapy.
• Hormone therapy comes with changes such as hot flashes, decreased libido, fatigue, muscle loss with increased body fat, and reduced bone density, so exercise and bone density monitoring are managed alongside treatment.

Why Does Hormone Therapy Duration Differ From Person to Person?

• Treatment decisions in prostate cancer are not based on stage alone — they're determined by a combination of PSA level, Gleason score (grade group), stage, age, life expectancy, and coexisting conditions, which together define the risk group.
• Generally, lower-risk cases call for shorter or no hormone therapy, while higher-risk cases call for longer combined treatment. Low-risk disease often doesn't require immediate treatment at all — active surveillance, which involves watchful monitoring, is a standard option, so hormone therapy itself is frequently not used.
• For intermediate-risk disease, both surgery and radiation therapy are standard options. If radiation is chosen, a short course of hormone therapy may be added depending on specific conditions.
• For high-risk or locally advanced disease, combining radiation therapy with several years of hormone therapy is part of the standard approach.

How Long Does Hormone Therapy Continue in Metastatic Disease?

• In metastatic prostate cancer, hormone therapy that blocks testosterone forms the backbone of treatment, and it has now become standard to combine it from the outset with stronger anti-androgen agents or chemotherapy.
• Since the goal at this stage is not cure but long-term disease control, hormone therapy is generally continued as long as it remains effective.
• If hormone therapy stops working, other classes of medication, chemotherapy, or radioligand therapy (a method targeting PSMA) are considered. When bone metastases are present, bone-protective medications and pain-relieving radiation therapy are added.
• If genetic alterations such as BRCA are present, matching targeted therapies are also considered.

What Is the Typical Treatment Pathway?

• Step 1: A PSA blood test, digital rectal exam, and prostate MRI are performed to check whether the cancer is confined to the prostate or may have spread.
• Step 2: A targeted biopsy of suspicious areas identified on MRI is performed to obtain the Gleason score and grade group.
• Step 3: For high-risk cases, a bone scan or PSMA PET scan checks for bone or lymph node metastasis, finalizing the risk classification.
• Step 4: Based on the risk group, treatment is divided into active surveillance, surgery, radiation (with or without combined hormone therapy), or hormone-therapy-centered treatment for metastatic disease.
• Step 5: After treatment, PSA-focused follow-up monitors for recurrence. For patients on hormone therapy, bone density, blood sugar, lipids, and cardiovascular risk are also monitored.

FAQ — In Russia, only hormone therapy was recommended, but are other treatment options available in Korea?

If the disease is still localized, curative-intent treatment through surgery or radiation may be possible in some cases. After reviewing the stage, risk group, and the duration of hormone therapy already received, it's possible to clarify what options remain available. However, the final decision is made by the treating medical team based on a comprehensive assessment of stage, Gleason grade group, age, and coexisting conditions.

FAQ — Can hormone injections be continued locally after returning home?

Yes, this is possible in many cases. The type and interval of injections, along with any oral medications, can be organized into a prescription plan, and because drug availability differs by country, alternative medications can be noted as well. After returning home, local medical staff can take over care using a handover document that specifies upcoming test dates and target value ranges.

Sources and Notes

• This article was written based on general explanations drawn from the National Cancer Registration Statistics 2019–2023 (Central Cancer Registry, National Cancer Center Korea) and patient guideline-level information from the National Cancer Information Center and NCCN.
• This content is intended for general medical information purposes only. Actual diagnosis, treatment methods, and outcomes may vary depending on individual conditions. Accurate diagnosis and treatment decisions should always be made in consultation with a medical professional.